Acticomp registered in Russia a German-made rapid test for COVID-19 antibodies

25 June 2020

Acticomp entered into an exclusive agreement with the world leader in the field of in vitro diagnostics – nal von minden GmbH (Germany) – on the supply of rapid testing systems for antibodies to COVID-19 to Russia and registered them in the Russian Federation (RU RZN 2020/11034 dated 26.06.2020). The companies are considering the possibility of local production of testing systems of the German manufacturer by Acticomp, as well as expanding the range of supplied diagnostic mechanisms.

NADAL® COVID-19 IgG/IgM tests are a proprietary development of nal von minden, already used in 57 countries of the world (Austria, UK, Germany, Spain, Italy, Portugal, France, among others). In total, more than 4 million tests have been carried out in the world to date. The tests were certified by the EU, and Acticomp registered the tests in the Russian Federation with the necessary clinical and laboratory studies at the Central Clinical Hospital of the Russian Academy of Sciences. As a result of studies, the quality, effectiveness and safety of the testing systems have been confirmed. The diagnostic sensitivity is 98.8%, the specificity is 98.7%. These tests are convenient to use, since whole blood from a finger can be used for analysis: this procedure does not require special training of medical personnel or special equipment. The test result is available within 15 minutes.

The diagnostic sensitivity is 98.8%, the specificity is 98.7%. These tests are convenient to use, since whole blood from a finger can be used for analysis: this procedure does not require special training of medical personnel or special equipment. The test result is available within 15 minutes. Rapid testing for antibodies to coronavirus is recommended by the Ministry of Health of the Russian Federation for all patients admitted to medical organizations for the provision of routine medical care. Rapid tests can also be used by employers for routine and large-scale testing of employees in offices and enterprises, as well as employees and visitors of social organizations. In June 2020, the company donated tests to medical institutions in the Kolpinsky and Pushkinsky districts (St. Petersburg) for doctors and other hospital workers.

Alexander Semenov, President of Acticomp: "Testing systems are a new direction for Active Component, which we are developing as we understand our responsibility to our families, employees and society. The fight against the virus is not over yet, and we believe that rapid tests will be in demand by business and social organizations, as it will be necessary to pay special attention to monitoring the health of employees and visitors until the end of 2020 at least. It is possible that such testing will be included in one of the usual procedures in companies and social institutions along with temperature measurements. Therefore, we plan to establish not only the supply of NADAL® COVID-19 IgG/IgM express tests to Russia and other countries, but also the production of rapid tests at our plant."

nal von minden GmgH

European leader with 35 years of experience in developing, manufacturing and supplying in vitro diagnostic systems. The company has 2 production sites in Germany and representative offices in several EU countries. The nal von minden GmbH portfolio includes more than 3,000 products. Website: https://www.nal-vonminden.com/en/